News - Temsirolimus Shows Promise for Ovarian, Peritoneal Cancers: Presented at SGO

"The researchers concluded that temsirolimus may have modest cytostatic activity in patients with prior chemotherapy and should be investigated further. Dr. Behbakht suggested that the agent might be combined with bevacizumab for increased activity and is already being studied in combination with paclitaxel. He noted that isolation, enumeration, and characterisation of CTCs from patients should also be investigated in further trials."